Evidence map›Paper›PMID 37764428›Full record

ReviewMolecules (Basel, Switzerland)2023

Drug Delivery and Therapy Strategies for Osteoporosis Intervention.

Mingyang Ma, Huiling Zeng, Pei Yang, Jiabing Xu, Xingwang Zhang, Wei He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. The link between osteoporosis and cardiovascular diseases: a review of shared mechanisms, risk factors, and therapeutic approaches.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mingyang MaSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Huiling ZengSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Pei YangSchool of Science, China Pharmaceutical University, Nanjing 211198, China.
Jiabing XuTaizhou Institute for Drug Control, Taizhou 225316, China.
Xingwang ZhangDepartment of Pharmaceutics, School of Pharmacy, Jinan University, Guangzhou 510632, China.ORCID 0000-0002-8824-3917
Wei HeShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.ORCID 0000-0003-3075-3831

Funding

the National Natural Science Foundation of China and the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine Nos. 82073782 and 82241002; zdsys-202103, China
6 · The paper itself

Abstract

With the advent of the aging society, osteoporosis (OP) risk increases yearly. Currently, the clinical usage of anti-OP drugs is challenged by recurrent side effects and poor patient compliance, regardless of oral, intravenous, or subcutaneous administration. Properly using a drug delivery system or formulation strategy can achieve targeted drug delivery to the bone, diminish side effects, improve bioavailability, and prolong the in vivo residence time, thus effectively curing osteoporosis. This review expounds on the pathogenesis of OP and the clinical medicaments used for OP intervention, proposes the design approach for anti-OP drug delivery, emphatically discusses emerging novel anti-OP drug delivery systems, and enumerates anti-OP preparations under clinical investigation. Our findings may contribute to engineering anti-OP drug delivery and OP-targeting therapy.

Indexed as

Drug-Related Side Effects and Adverse ReactionsOsteoporosisAdministration, IntravenousAgingBiological AvailabilityDrug Delivery SystemsHumansbone tissue engineeringdrug deliverymicroneedlesosteoporosistargeted drug delivery

Identifiers

PMID37764428
PMCPMC10534890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.